NCT03258593 2026-03-17
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
8 trialsNCT07417488 2026-02-27
GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas
Thomas Jefferson University
Phase 1 Not yet recruiting
NCT03388619 2026-02-23
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT06122610 2026-01-15
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 1 Recruiting
NCT05035407 2025-12-02
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT04933617 2024-07-09
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02809690 2023-09-07
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
University of Southern California
Phase 1 Terminated
NCT02717572 2019-04-05
18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR
Washington University School of Medicine
Phase 1 Completed